Post Depomed Deal Flop, Horizon Buys Crealta For $510m

Horizon Pharma plc has moved on from its failed $1.7bn attempt to buy Depomed Inc. with the $510m cash purchase of Crealta Holdings LLC, which bought the developer of specialty gout drug Krystexxa (pegloticase) out of bankruptcy two years ago for $120.4m.